Published in J Clin Oncol on December 01, 2008
Radiation- Induced Alopecia in Patients Undergoing Radiation Therapy to the Brain | NCT03543020
Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol (2010) 2.71
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. Int J Radiat Oncol Biol Phys (2013) 1.24
Therapeutic procedure in small cell lung cancer. J Thorac Dis (2013) 1.06
Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis. Ann Oncol (2012) 1.03
Quality of life of long-term survivors after a distal subtotal gastrectomy. Cancer Res Treat (2010) 1.01
Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana. Radiol Oncol (2010) 0.98
Progress in the management of limited-stage small cell lung cancer. Cancer (2013) 0.93
Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases. BMC Cancer (2012) 0.91
Cognitive Sparing during the Administration of Whole Brain Radiotherapy and Prophylactic Cranial Irradiation: Current Concepts and Approaches. J Oncol (2010) 0.89
Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. Neuro Oncol (2015) 0.85
A pilot study using dynamic contrast enhanced-MRI as a response biomarker of the radioprotective effect of memantine in patients receiving whole brain radiotherapy. Oncotarget (2016) 0.84
Treatment for small cell lung cancer, where are we now?-a review. Transl Lung Cancer Res (2016) 0.84
Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases. Oncotarget (2016) 0.83
Proxy assessment of patients before and after radiotherapy for brain metastases. Results of a prospective study using the DEGRO brain module. Strahlenther Onkol (2012) 0.81
First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Res Notes (2015) 0.80
Prophylactic cranial irradiation after definitive chemoradiotherapy for limited-stage small cell lung cancer: Do all patients benefit? Radiother Oncol (2017) 0.78
Hair-sparing whole brain radiotherapy with volumetric arc therapy in patients treated for brain metastases: dosimetric and clinical results of a phase II trial. Radiat Oncol (2014) 0.78
Potential toxicities of prophylactic cranial irradiation. Transl Lung Cancer Res (2012) 0.77
Assessing measurement invariance of a health-related quality-of-life questionnaire in radiotherapy patients. Qual Life Res (2011) 0.77
Chemotherapy as primary treatment for brain metastases from breast cancer: analysis of 115 one-year survivors. J Cancer Res Clin Oncol (2012) 0.77
Identification of breast cancer patients with a high risk of developing brain metastases: a single-institutional retrospective analysis. BMC Cancer (2014) 0.76
Dosimetric analysis of the alopecia preventing effect of hippocampus sparing whole brain radiation therapy. Radiat Oncol (2015) 0.76
Chemotherapy for small cell lung cancer: a comprehensive review. Oncol Rev (2012) 0.75
Tolerability and toxicity of prophylactic cranial irradiation in patients with non-small cell lung cancer - Results of a phase II study (with estimation of hematological toxicity, pituitary function and magnetic resonance spectra changes). Rep Pract Oncol Radiother (2014) 0.75
Radiotherapy: prophylactic cranial irradiation for small-cell lung cancer. Nat Rev Clin Oncol (2009) 0.75
Consolidative thoracic radiotherapy for extensive stage small cell lung cancer. Oncotarget (2017) 0.75
Lung cancer. BMJ Clin Evid (2010) 0.75
The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature. Front Pharmacol (2017) 0.75
Analyses of distribution and dosimetry of brain metastases in small cell lung cancer with relation to the neural stem cell regions: feasibility of sparing the hippocampus in prophylactic cranial irradiation. Radiat Oncol (2017) 0.75
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst (1993) 38.99
Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol (1998) 9.89
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol (2006) 7.87
Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med (2007) 6.55
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med (1999) 4.81
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst (1995) 3.25
The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res (1996) 2.76
Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer (2001) 1.44
Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol (2007) 1.42
Health related quality of life outcomes in cancer clinical trials. Eur J Cancer (2005) 1.31
Health related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients. Eur J Cancer (2002) 1.18
Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. Radiother Oncol (1998) 0.98
Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer. Eur J Cancer (1993) 0.90
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol (2007) 18.32
Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med (2006) 12.50
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet (2002) 10.17
Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol (2007) 7.51
Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet (2005) 6.99
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (2012) 6.61
Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med (2007) 6.55
Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol (2007) 6.23
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol (2010) 6.15
Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med (2009) 5.82
Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. N Engl J Med (2015) 5.08
Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol (2005) 4.98
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol (2011) 4.66
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol (2010) 4.61
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst (2007) 4.40
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol (2006) 4.36
Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J (2007) 3.87
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet (2002) 3.67
Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. J Clin Oncol (2005) 3.31
The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol (2008) 3.14
Volumetric intensity-modulated arc therapy vs. conventional IMRT in head-and-neck cancer: a comparative planning and dosimetric study. Int J Radiat Oncol Biol Phys (2009) 3.13
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol (2007) 2.90
Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys (2010) 2.84
Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys (2012) 2.80
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet (2008) 2.77
Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell (2012) 2.76
Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension. Eur Heart J (2008) 2.73
Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension. Chest (2007) 2.68
Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol (2010) 2.66
Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol (2009) 2.64
Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol (2012) 2.64
Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol (2002) 2.63
Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst (2011) 2.56
Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys (2011) 2.54
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 2.50
Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol (2010) 2.46
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg (2012) 2.43
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol (2012) 2.36
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol (2012) 2.33
The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol (2009) 2.29
Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol (2009) 2.26
Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol (2005) 2.26
Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.22
Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol (2013) 2.21
What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer? BJU Int (2006) 2.03
Whole-brain radiotherapy with simultaneous integrated boost to multiple brain metastases using volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys (2009) 2.03
Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol (2006) 2.01
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol (2013) 1.99
The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer (2005) 1.97
An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer (2008) 1.95
What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol (2004) 1.89
Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. Radiother Oncol (2008) 1.88
The Mesothelioma and Radical surgery randomized controlled trial: the Mars feasibility study. J Thorac Oncol (2009) 1.87
Stereotactic radiotherapy for peripheral lung tumors: a comparison of volumetric modulated arc therapy with 3 other delivery techniques. Radiother Oncol (2010) 1.86
An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer (2010) 1.84
Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol (2011) 1.80
Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol (2009) 1.76
Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients. Chest (2007) 1.74
Guidelines on the radical management of patients with lung cancer. Thorax (2010) 1.73
Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol (2007) 1.72
Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol (2005) 1.70
Use of maximum intensity projections (MIP) for target volume generation in 4DCT scans for lung cancer. Int J Radiat Oncol Biol Phys (2005) 1.67
Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol (2010) 1.66
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol (2010) 1.65
Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol (2006) 1.64
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol (2013) 1.62
Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach. Eur J Cancer (2007) 1.62
Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.62
Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'. Eur J Cancer (2008) 1.61
Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol (2011) 1.60
Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol (2011) 1.54
Rapid delivery of stereotactic radiotherapy for peripheral lung tumors using volumetric intensity-modulated arcs. Radiother Oncol (2009) 1.49
Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol (2012) 1.49
Early changes of cardiac structure and function in COPD patients with mild hypoxemia. Chest (2005) 1.48
European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol (2010) 1.48
The natural course of preneoplastic lesions in bronchial epithelium. Clin Cancer Res (2005) 1.45
Do quality-of-life randomized clinical trials support clinicians in their decision-making? J Clin Oncol (2002) 1.45
Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report. J Thorac Oncol (2010) 1.44